These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


113 related items for PubMed ID: 24055353

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011.
    Tse A, Tseng HF, Greene SK, Vellozzi C, Lee GM, VSD Rapid Cycle Analysis Influenza Working Group.
    Vaccine; 2012 Mar 02; 30(11):2024-31. PubMed ID: 22361304
    [Abstract] [Full Text] [Related]

  • 3. Systematic review of fever, febrile convulsions and serious adverse events following administration of inactivated trivalent influenza vaccines in children.
    Li-Kim-Moy J, Yin JK, Rashid H, Khandaker G, King C, Wood N, Macartney KK, Jones C, Booy R.
    Euro Surveill; 2015 Jun 18; 20(24):. PubMed ID: 26111238
    [Abstract] [Full Text] [Related]

  • 4. Febrile events including convulsions following the administration of four brands of 2010 and 2011 inactivated seasonal influenza vaccine in NZ infants and children: the importance of routine active safety surveillance.
    Petousis-Harris H, Poole T, Turner N, Reynolds G.
    Vaccine; 2012 Jul 13; 30(33):4945-52. PubMed ID: 22664224
    [Abstract] [Full Text] [Related]

  • 5. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003.
    McMahon AW, Iskander J, Haber P, Chang S, Woo EJ, Braun MM, Ball R.
    Pediatrics; 2005 Feb 13; 115(2):453-60. PubMed ID: 15687455
    [Abstract] [Full Text] [Related]

  • 6. Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age.
    Rosenberg M, Sparks R, McMahon A, Iskander J, Campbell JD, Edwards KM.
    Vaccine; 2009 Jul 09; 27(32):4278-83. PubMed ID: 19450636
    [Abstract] [Full Text] [Related]

  • 7. Reactogenicity of two 2010 trivalent inactivated influenza vaccine formulations in adults.
    Leeb A, Carcione D, Richmond PC, Jacoby P, Effler PV.
    Vaccine; 2011 Oct 19; 29(45):7920-4. PubMed ID: 21864621
    [Abstract] [Full Text] [Related]

  • 8. Update: Recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding use of CSL seasonal influenza vaccine (Afluria) in the United States during 2010-11.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2010 Aug 13; 59(31):989-92. PubMed ID: 20703207
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Trivalent influenza vaccine and febrile adverse events in Australia, 2010: clinical features and potential mechanisms.
    Blyth CC, Currie AJ, Wiertsema SP, Conway N, Kirkham LA, Fuery A, Mascaro F, Geelhoed GC, Richmond PC.
    Vaccine; 2011 Jul 18; 29(32):5107-13. PubMed ID: 21640152
    [Abstract] [Full Text] [Related]

  • 11. Risk of convulsions in children after monovalent H1N1 (2009) and trivalent influenza vaccines: a database study.
    Stowe J, Andrews N, Bryan P, Seabroke S, Miller E.
    Vaccine; 2011 Nov 28; 29(51):9467-72. PubMed ID: 22019757
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Oil-in-water emulsion adjuvant with influenza vaccine in young children.
    Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt HJ, Baehner F, Borkowski A, Tsai TF, Clemens R.
    N Engl J Med; 2011 Oct 13; 365(15):1406-16. PubMed ID: 21995388
    [Abstract] [Full Text] [Related]

  • 14. Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink.
    Glanz JM, Newcomer SR, Hambidge SJ, Daley MF, Narwaney KJ, Xu S, Lee GM, Baggs J, Klein NP, Nordin JD, Naleway AL, Belongia EA, Weintraub ES.
    Arch Pediatr Adolesc Med; 2011 Aug 13; 165(8):749-55. PubMed ID: 21810637
    [Abstract] [Full Text] [Related]

  • 15. Safety and tolerability of a 2009 trivalent inactivated split-virion influenza vaccine in infants, children and adolescents.
    Lambert SB, Chuk LM, Nissen MD, Nolan TM, McVernon J, Booy R, Heron L, Richmond PC, Walls T, Marshall HS, Reynolds GJ, Hartel GF, Hu W, Lai MH.
    Influenza Other Respir Viruses; 2013 Sep 13; 7(5):676-85. PubMed ID: 23551933
    [Abstract] [Full Text] [Related]

  • 16. Fever following administration of two inactivated influenza vaccines--a survey of parents of New Zealand infants and children 5 years of age and under.
    Petousis-Harris H, Poole T, Booy R, Turner N.
    Vaccine; 2011 Apr 05; 29(16):2933-7. PubMed ID: 21338679
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.
    Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, Øymar K, Garcia ML, Krygier A, Costa H, Heininger U, Pregaldien JL, Cheng SM, Skinner J, Razmpour A, Saville M, Gruber WC, Forrest B, CAIV-T Asthma Study Group.
    Pediatr Infect Dis J; 2006 Oct 05; 25(10):860-9. PubMed ID: 17006278
    [Abstract] [Full Text] [Related]

  • 18. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.
    Englund JA, Walter E, Black S, Blatter M, Nyberg J, Ruben FL, Decker MD, GRC28 Study Team.
    Pediatr Infect Dis J; 2010 Feb 05; 29(2):105-10. PubMed ID: 19934787
    [Abstract] [Full Text] [Related]

  • 19. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM.
    Pediatrics; 2006 Sep 05; 118(3):e579-85. PubMed ID: 16950949
    [Abstract] [Full Text] [Related]

  • 20. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.
    Langley JM, Aoki F, Ward BJ, McGeer A, Angel JB, Stiver G, Gorfinkel I, Shu D, White L, Lasko B, Dzongowski P, Papp K, Alexander M, Boivin G, Fries L.
    Vaccine; 2011 Feb 24; 29(10):1921-8. PubMed ID: 21219987
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 6.